Quan L, Zhu B-L, Ishikawa T, Michiue T, Zhao D, Li D-R, Ogawa M, Maeda H
Department of Legal Medicine, Osaka City University Medical School, Asahi-machi 1-4-3, Abeno, 545-8585, Osaka, Japan.
Int J Legal Med. 2008 Nov;122(6):481-7. doi: 10.1007/s00414-008-0276-9. Epub 2008 Aug 6.
Circulating erythropoietin (EPO) is mainly produced in the kidneys, depending on blood oxygen level. The present study investigated the postmortem serum EPO levels with regard to the cause of death and survival time. Serial medicolegal autopsy cases of postmortem time within 48 h (n = 536) were examined. Serum EPO levels were within the clinical reference range in most cases. Uremic patients with medical administration of an EPO agent (n = 11) showed a markedly high level (140-4,850 mU/ml; median, 1,798 mU/ml). Otherwise, an elevation in serum EPO level (>30 mU/ml) was mainly seen in protracted deaths due to blunt injury and fire fatality, depending on the survival time (r = 0.69, p < 0.0001, and r = 0.45, p < 0.0001, respectively), and in subacute deaths from gastrointestinal bleeding and infectious diseases. However, mildly to moderately elevated serum EPO levels were sporadically found in acute deaths due to mechanical asphyxiation, fire fatality, and acute ischemic heart disease, and in fatal hypothermia cases, especially for elderly subjects. Protracted deaths due to mechanical asphyxiation and ischemic heart disease did not show any survival time-dependent increase in serum EPO level (p > 0.05). EPO was immunohistochemically detected in the tubular epithelia and interstitial cells, showing no evident difference among the causes of death, independent of survival time or serum level. These findings suggest that serum EPO can be used as a marker for investigating anemia and/or hypoxia as a consequence of fatal insult in subacute or prolonged deaths, or a predisposition to traumatic deaths or fatal heart attacks in acute deaths.
循环中的促红细胞生成素(EPO)主要由肾脏产生,取决于血氧水平。本研究调查了死后血清EPO水平与死亡原因及生存时间的关系。对死后时间在48小时内的一系列法医学尸检病例(n = 536)进行了检查。大多数病例的血清EPO水平在临床参考范围内。接受EPO制剂治疗的尿毒症患者(n = 11)血清EPO水平显著升高(140 - 4850 mU/ml;中位数为1798 mU/ml)。此外,血清EPO水平升高(>30 mU/ml)主要见于钝器伤和火灾致死导致的迁延性死亡,且与生存时间相关(分别为r = 0.69,p < 0.0001和r = 0.45,p < 0.0001),以及胃肠道出血和传染病导致的亚急性死亡。然而,在机械性窒息、火灾致死和急性缺血性心脏病导致的急性死亡以及致命性低温病例中,尤其是老年患者,偶尔会发现血清EPO水平轻度至中度升高。机械性窒息和缺血性心脏病导致的迁延性死亡未显示血清EPO水平随生存时间有任何增加(p > 0.05)。免疫组化检测发现肾小管上皮细胞和间质细胞中有EPO表达,不同死亡原因之间无明显差异,与生存时间或血清水平无关。这些发现表明,血清EPO可作为一种标志物,用于调查亚急性或迁延性死亡中因致命性损伤导致的贫血和/或缺氧,或急性死亡中创伤性死亡或致命性心脏病发作的易感性。